TASER International, Inc. Reports Record First Quarter Revenue

$15.3 Million of Revenue, $0.3 Million Operating Income, $0.5 Million Net Income and $0.01 Basic and Diluted EPS for First Quarter 2007


SCOTTSDALE, Ariz., April 25, 2007 (PRIME NEWSWIRE) -- TASER International, Inc. (Nasdaq:TASR), a market leader in advanced electronic control devices, today reported financial results for first quarter of 2007.

For the first quarter of 2007 revenues were $15.3 million, the highest first quarter in the Company's history and a 10% increase over the same quarter of the prior year. Income from operations for the first quarter was $0.3 million. Net income and basic and diluted earnings per share for the first quarter of 2007 were $0.5 million and $0.01, respectively.

Significant events in the first quarter of 2007 include:


   1. We successfully debuted the TASER(r) C2 personal protector
      at the Consumer Electronics Show in January 2007. This new
      device is a compact system that provides the same proven
      Neuro-Muscular Incapacitation (NMI) effectiveness as our
      market leading TASER X26C but in a form factor and at a
      price point that will be more attractive to private citizens.
      The TASER C2 also promotes responsible ownership and aims to
      prevent misuse with the introduction of a background check
      system whereby the device remains inactive until the owner
      has successfully completed a background check either online
      or via a toll-free telephone number. In addition the TASER
      C2 cartridges each have a unique serial number and are
      equipped with Anti-Felon Identification tags, which are
      dispersed upon deployment and which would allow the police
      to track a potential misuse.  We expect to begin shipments
      of the TASER C2 in the second quarter of 2007.

   2. Fourteen more product liability suits were dismissed
      during the quarter representing a total of forty-four
      wrongful death or injury suits that have been dismissed
      or judgment entered in favor of the Company since 2004.

   3. A landmark medical study published in the Society for
      Academic Emergency Medicine found that the prolonged
      exposure from a TASER X26 Electronic Control Device has
      no abnormal respiratory effects on human subjects. This
      study can be viewed at:
      http://www.aemj.org/cgi/content/full/14/3/197

"We believe the first quarter results, with the highest first quarter revenues in our Company's history, have given us a solid start to 2007," commented Tom Smith, Chairman of TASER International, Inc. "We are continuing to build on the momentum generated in 2006, and we believe the investments we have made in developing new products during 2006 and in the first quarter of 2007 will provide us with the platform to further enhance our position as a market leader in advanced personal protection devices. In particular, we believe the commencement of sales of the TASER C2 in the second quarter will provide the consumer with next generation, life protecting technologies which are designed to maximize public safety and minimize the potential for misuse."

The Company hosts its first quarter 2007 earnings conference call on Wednesday, April 25, 2007 at 10:00 a.m. ET. The conference call is available via web cast and can be accessed on the "Investor Relations" page at www.TASER.com. To access the teleconference, please dial: 1-800-599-9816 or 1-617-847-8705 for international callers. The pass code is 45846998 for both numbers.

About TASER International, Inc.

TASER International, Inc. provides advanced non-lethal devices for use in the law enforcement, military, private security and personal defense markets. TASER devices use proprietary technology to safely incapacitate dangerous, combative, or high-risk subjects who pose a risk to law enforcement officers, innocent citizens or themselves. TASER technology saves lives every day, and the use of TASER devices dramatically reduces injury rates for police officers, and suspects.

The TASER International logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2931

Note to Investors

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including statements, without limitation, regarding our expectations, beliefs, intentions or strategies regarding the future. We intend that such forward-looking statements be subject to the safe-harbor provided by the Private Securities Litigation Reform Act of 1995. The forward-looking information is based upon current information and expectations regarding TASER International, Inc. These estimates and statements speak only as of the date on which they are made, are not guarantees of future performance, and involve certain risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results could materially differ from what is expressed, implied, or forecasted in such forward-looking statements.

TASER International, Inc. assumes no obligation to update the information contained in this press release. These statements are qualified by important factors that could cause our actual results to differ materially from those reflected by the forward-looking statements. Such factors include but are not limited to: (1) market acceptance of our products; (2) our ability to establish and expand direct and indirect distribution channels; (3) our ability to attract and retain the endorsement of key opinion-leaders in the law enforcement community; (4) the level of product technology and price competition for our products; (5) the degree and rate of growth of the markets in which we compete and the accompanying demand for our products; (6) risks associated with rapid technological change and new product introductions; (7) competition; (8) litigation including lawsuits resulting from alleged product related injuries and death; (9) media publicity concerning allegations of deaths and injuries occurring after use of the TASER device and the negative effect this publicity could have on our sales; (10) TASER device tests and reports; (11) product quality; (12) implementation of manufacturing automation; (13) potential fluctuations in our quarterly operating results; (14) financial and budgetary constraints of prospects and customers; (15) order delays; (16) dependence upon sole and limited source suppliers; (17) negative reports concerning TASER device uses; (18) fluctuations in component pricing; (19) government regulations and inquiries; (20) dependence upon key employees and our ability to retain employees; (21) execution and implementation risks of new technology; (22) ramping manufacturing production to meet demand; (23) medical and safety studies and (24) other factors detailed in our filings with the Securities and Exchange Commission, including, without limitation, those factors detailed in the Company's Annual Report on Form 10-K and its Form 10-Qs.

The statements made herein are independent statements of TASER International, Inc. The inclusion of any third parties does not represent an endorsement of any TASER International products or services by any such third parties.

For further information contact Marcy Rigoni, Manager of Investor Relations at Marcy@TASER.com or call 800-978-2737 ext. 2011, or Dan Behrendt, Chief Financial Officer of TASER International, Inc., 480-905-2002.


                      TASER International, Inc.
                         Statements of Income
                              (Unaudited)


                                         For the Three Months Ended
                                         --------------------------
                                        March 31,           March 31, 
                                          2007                2006
                                       -----------         -----------

 Net Sales                             $15,301,815         $13,893,563
                                       -----------         -----------

 Cost of Products Sold:
 Direct manufacturing expense            4,608,569           3,529,401
 Indirect manufacturing expense
  (including stock-based 
  compensation expense of 
  $31,698 and $31,834,
  respectively)                          1,804,217           1,409,468
                                       -----------         -----------

 Total Cost of Products Sold             6,412,786           4,938,869
                                       -----------         -----------

 Gross Margin                            8,889,029           8,954,694

 Sales, general and administrative
  expenses (including stock-based
  compensation expense of $187,773
  and $267,144 respectively)             7,581,908           7,254,312
 Research and development expenses
  (including stock-based 
  compensation expense of $42,692 
  and $63,022, respectively)               970,786             663,810
                                       -----------         -----------

 Income from Operations                    336,335           1,036,572

 Interest income                           507,869             367,435
 Interest expense                           (1,500)             (2,007)
 Other income (expense), net                    --                (112)
                                       -----------         -----------

 Income before provision for income
  taxes                                    842,704           1,401,888
 Provision for income taxes                348,150             595,909
                                       -----------         -----------

 Net Income                            $   494,554         $   805,979
                                       ===========         ===========

 Income per common and common 
  equivalent shares
 Basic                                 $      0.01         $      0.01
 Diluted                               $      0.01         $      0.01

 Weighted average number of common 
  and common equivalent shares 
  outstanding
 Basic                                  62,010,198          61,947,048
 Diluted                                64,692,636          64,053,031


                       TASER International, Inc.
                            Balance Sheet
                             (Unaudited)


                                       March 31,         December 31,
                                         2007                2006
                                     ------------        ------------

                              ASSETS

 Current Assets
 Cash and cash equivalents           $ 16,073,479        $ 18,773,685
 Short-term investments                        --           3,557,289
 Accounts receivable, net               7,493,522          10,068,049
 Inventory                             10,311,705           9,257,746
 Prepaids and other assets              2,248,299           2,164,002
 Current deferred income tax asset      9,794,566          12,295,493
                                     ------------        ------------

 Total Current Assets                  45,921,571          56,116,264
 Long-term investments                 25,483,105          25,477,574
 Property and equipment, net           21,344,706          20,842,632
 Deferred income tax asset             17,851,764          15,868,719
 Intangible assets, net                 1,698,812           1,532,500
                                     ------------        ------------

 Total Assets                        $112,299,958        $119,837,689
                                     ============        ============



                  LIABILITIES AND STOCKHOLDERS' EQUITY

 Current Liabilities
 Current portion of capital lease
  obligations                        $     45,774        $     45,214
 Accounts payable and accrued 
  liabilities                           6,056,758           6,789,474
 Current deferred revenue               1,105,871           1,037,441
 Deferred insurance settlement
  proceeds                                476,139             509,067
 Customer deposits                        208,653             171,492
 Litigation settlement liabilities      1,750,000           9,750,000
                                     ------------        ------------

 Total Current Liabilities              9,643,195          18,302,688
 Capital lease obligations, net of
  current portion                          19,314              30,974
 Deferred revenue, net of current 
  portion                               2,072,223           1,975,489
 Other liabilities                             --             199,999
                                     ------------        ------------

 Total Liabilities                     11,734,732          20,509,150
                                     ------------        ------------

 Commitments and Contingencies                 --                  --

 Stockholders' Equity
 Common stock                                 623                 622
 Additional paid-in capital            81,371,791          80,629,659
 Treasury stock                        (2,208,957)         (2,208,957)
 Retained earnings                     21,401,769          20,907,215
                                     ------------        ------------

 Total Stockholders' Equity           100,565,226          99,328,539
                                     ------------        ------------

 Total Liabilities and 
  Stockholders' Equity               $112,299,958        $119,837,689
                                     ============        ============


                      TASER International, Inc.
             Selected Statements of Cash Flows Information
                              (Unaudited)


                                          For the Three Months Ended
                                        March 31,           March 31, 
                                          2007                2006
                                      ------------        ------------

 Net income                           $    494,554        $    805,979
 Depreciation and amortization             569,324             516,740
 Stock-based compensation expense          262,163             362,000
 Net cash provided (used) by                           
  operating activities                  (5,483,124)          1,962,862
 Net cash provided (used) by                           
  investing activities                   2,314,048          (4,135,742)
 Net cash provided by financing                        
  activities                               468,870              88,430
 Cash and Cash Equivalents, end                        
  of period                           $ 16,073,479        $ 14,267,459

 ---------------------------------------------------------------------


            

Contact Data